Back

Clearmind highlights new U.S. regulatory steps on psychedelic treatment development

The company pointed to final FDA guidance, a planned public hearing, and new inter-agency initiatives involving HHS, VA, NIDA, ARPA-H and HRSA.

Summary

verifying reliability

Terms & Concepts

No specialized terms available for this topic.